COSCIENS Biopharma announced its Q3 2026 financial results, reporting a net loss of $3.4 million for the quarter but a net income of $7.1 million for the first nine months of 2026. The company highlighted its acquisition of Nualtis Corp., a leader in pharmaceutical oral thin film manufacturing, which is expected to drive future growth with product launches starting in Q4 2026. COSCIENS also updated on its convertible debenture offering and noted cost-saving measures including divestment of German businesses and suspension of SEC reporting. The acquisition and operational improvements position COSCIENS for potential profitability and expansion in the pharmaceutical and active ingredient markets.
COSCIENS Biopharma's recent financial update comes as a backdrop to a broadly positive health sector on Pluang, where 107 of 150 US health stocks rose today. For readers following the health sector, here is Pluang's market snapshot as of Nov 13, 2026 20:42 WIB: Heron Therapeutics Inc (HRTX) rose 5.80% to USD 0.35 with a typical hold time of 39 days and balanced buy/sell activity, while Citius Pharmaceuticals Inc (CTXR) fell 4.21% to USD 0.51 with 84% sell orders, and Tango Therapeutics Inc (TNGX) declined 3.42% to USD 24.00 with a typical hold time of 4 days.
On November 12, 2026, Nokia executive Pallavi Mahajan acquired 89 shares of Nokia Corporation at a price of €7.63 per share. This insider purchase is officially reported under EU Market Abuse Regulation Article 19. Such transactions by company execut...
David Heard, a senior manager at Nokia Corporation, purchased 1,139 shares of the company on November 12, 2026, at a price of €7.63 per share. This transaction was reported under EU Market Abuse Regulation, signaling insider confidence or strategic i...
Victoria Hanrahan, a senior executive at Nokia Corporation, purchased 6 shares of Nokia stock at a price of €7.63 per share on November 12, 2026. This transaction was reported under EU Market Abuse Regulation Article 19, indicating transparency in in...
Louise A. Fisk, a senior executive at Nokia Corporation, acquired 235 shares of Nokia stock at a price of €7.63 per share on November 12, 2026. This transaction was reported under the EU Market Abuse Regulation, signaling insider activity. Such purch...
Nokia executive David A. Heard purchased 1,139 shares of Nokia stock at a price of €7.63 per share on November 12, 2026. This transaction was reported under EU Market Abuse Regulation Article 19, indicating compliance with market transparency rules. ...
